{
    "nctId": "NCT06021379",
    "briefTitle": "AryoTrust\u00ae (Trastuzumab) Safety Study",
    "officialTitle": "Post-marketing Surveillance for Evaluation of AryoTrust Safety in Iranian HER2-positive Breast Cancer Patients Undergoing Adjuvant Chemotherapy Regimens",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 597,
    "primaryOutcomeMeasure": "Evaluation of safety by incidence, severity, seriousness and causality relationship of reported AEs",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with HER2-positive breast cancer undergoing adjuvant chemotherapy regimens\n\nExclusion Criteria:\n\n* Patients who had received Trastuzumab as part of their therapy or were not candidates for treatment continuation after adjuvant chemotherapy",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}